Sector Chart Madrigal Pharmaceuticals, Inc.
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 510.04 USD | -0.06% |
|
+9.14% | -12.42% |
| 07-30 | Madrigal Pharmaceuticals Q2 Loss Widens, Revenue Increases | MT |
| 07-30 | Madrigal Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 11.78B | - | ||||
| 68.12B | |||||
| 55.18B | |||||
| 28.63B | - | ||||
| 23.53B | - | ||||
| 23.99B |
Select your edition
All financial news and data tailored to specific country editions
